Patent: 9,315,811
✉ Email this page to a colleague
Summary for Patent: 9,315,811
Title: | Methods for modulating kallikrein (KLKB1) expression |
Abstract: | Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema. |
Inventor(s): | Bhattacharjee; Gourab (San Diego, CA), Revenko; Alexey (San Diego, CA), MacLeod; Robert A. (San Diego, CA) |
Assignee: | Ionis Pharmaceuticals, Inc. (Carlsbad, CA) |
Application Number: | 14/124,630 |
Patent Claims: | see list of patent claims |
Details for Patent 9,315,811
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Viropharma Biologics Llc | CINRYZE | c1 esterase inhibitor (human) | For Injection | 125267 | 10/10/2008 | ⤷ Try a Trial | 2031-06-10 |
Takeda Pharmaceuticals U.s.a., Inc. | KALBITOR | ecallantide | Injection | 125277 | 12/01/2009 | ⤷ Try a Trial | 2031-06-10 |
Csl Behring Gmbh | BERINERT | c1 esterase inhibitor (human) | For Injection | 125287 | 10/09/2009 | ⤷ Try a Trial | 2031-06-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |